Proton pump inhibitors: consequences of changes in reimbursement

Since January 1, 2012 antacids are not always reimbursed anymore. The Dutch Parliament wants insight into effects of this measure.
• How many of the people with an increased risk of gastrointestinal bleeding started with antacids in the period 2010-2013? What are their characteristics?
• How much extra gastrointestinal bleedings occured since the reimbursement measure was introduced?
• What are the costs of care as a result of not using antacids in the years 2010-2013?
The research questions are answered using the following three data sources:
• The NIVEL Primary Care Database that provides insight into the use of primary care
• The Foundation for Pharmaceutical Statistics which provides a link to hospital prescriptions
• DIS data to describe the hospital care that is generated by the reimbursement measure
A report containing the effects of the reimbursement measure with regard to:
- The number and type of patients with an increased risk of gastrointestinal bleeding that did not use an antacid;
- The extra care use and the extra costs as well as the savings the measure generates.